Dose escalation for prostate cancer radiotherapy: predictors of long-term biochemical tumor control and distant metastases-free survival outcomes.
about
Radioresistance of Brain TumorsExternal beam radiotherapy for localized prostate cancerThe effect of bowel preparation regime on interfraction rectal filling variation during image guided radiotherapy for prostate cancer.Significance of image guidance to clinical outcomes for localized prostate cancerSalvage low-dose-rate (125)I partial prostate brachytherapy after dose-escalated external beam radiotherapy.Perfusion CT is a valuable diagnostic method for prostate cancer: a prospective study of 94 patients.Clinical management and burden of prostate cancer: a Markov Monte Carlo model.Polymorphisms in DNA-repair genes in a cohort of prostate cancer patients from different areas in Spain: heterogeneity between populations as a confounding factor in association studies.A tissue biomarker-based model that identifies patients with a high risk of distant metastasis and differential survival by length of androgen deprivation therapy in RTOG protocol 92-02.Volumetric modulated arc therapy planning for primary prostate cancer with selective intraprostatic boost determined by 18F-choline PET/CT.Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate CancerHypofractionated external-beam radiotherapy for prostate cancer.Intraprostatic distribution and long-term follow-up after AdV-tk immunotherapy as neoadjuvant to surgery in patients with prostate cancer.Time to failure after definitive therapy for prostate cancer: implications for importance of aggressive local treatment.Classifying high-risk versus very high-risk prostate cancer: is it relevant to outcomes of conformal radiotherapy and androgen deprivation?An appraisal of analytical tools used in predicting clinical outcomes following radiation therapy treatment of men with prostate cancer: a systematic review.Current role of neoadjuvant and adjuvant systemic therapy for high-risk localized prostate cancer.Evolution of advanced technologies in prostate cancer radiotherapy.FROGG high-risk prostate cancer workshop: patterns of practice and literature review: part I: intact prostate.Improving outcomes in high-risk prostate cancer with radiotherapy.Hypofractioned radiotherapy in prostate cancer: is it the next step?Potential applications of image-guided radiotherapy for radiation dose escalation in patients with early stage high-risk prostate cancer.Synergistic action of image-guided radiotherapy and androgen deprivation therapy.Characterization of adenoviral transduction profile in prostate cancer cells and normal prostate tissue.Improved decision making in intermediate-risk prostate cancer: a multicenter study on pathologic and oncologic outcomes after radical prostatectomy.Potential role of CXCR3 in proliferation and invasion of prostate cancer cellsDevelopment of ProCaRS Clinical Nomograms for Biochemical Failure-free Survival Following Either Low-Dose Rate Brachytherapy or Conventionally Fractionated External Beam Radiation Therapy for Localized Prostate CancerAmerican Brachytherapy Society Task Group Report: Use of androgen deprivation therapy with prostate brachytherapy-A systematic literature review.Dependence of the safe rectum dose on the CTV-PTV margin size and treatment technique.Application of an interstitial and biodegradable balloon system for prostate-rectum separation during prostate cancer radiotherapy: a prospective multi-center study.PREDICT: model for prediction of survival in localized prostate cancer.Radical radiotherapy for high-risk prostate cancer in older menCryotherapy for primary treatment of prostate cancer: intermediate term results of a prospective study from a single institution.Predictors of distant metastasis after combined HDR brachytherapy and external beam radiation for prostate cancerStereotactic radiotherapy for prostate cancer: A review and future directions.Investigation of 90Y-avidin for prostate cancer brachytherapy: a dosimetric model for a phase I-II clinical study.Simultaneous integrated boost plan comparison of volumetric-modulated arc therapy and sliding window intensity-modulated radiotherapy for whole pelvis irradiation of locally advanced prostate cancer.A Phase II study of salvage high-dose-rate brachytherapy for the treatment of locally recurrent prostate cancer after definitive external beam radiotherapy.Hypofractionated stereotactic boost in intermediate risk prostate carcinoma: Preliminary results of a multicenter phase II trial (CKNO-PRO).Hydrogel spacers in prostate radiotherapy: a promising approach to decrease rectal toxicity.
P2860
Q26752579-A402102A-0242-4C91-AFF0-A6ED03249AF4Q26853068-31EEAEFD-2D6C-44AB-BFA3-C184CA766724Q33470011-42B9D88A-E5C4-4E89-A9C9-FDEB4864B965Q33993238-74D1BB21-3D71-4CD2-93C7-E6404E069EC9Q34355171-CAAE7C1A-80E1-429A-9BB2-5F0CB1CEE0C9Q34550344-0795EF91-9526-405D-932C-F66C12542353Q34634410-94AE7EEF-FB9C-4152-9D4B-F5A401BD683AQ34921055-559901BA-A0CD-4AC4-9B1C-E4800AE32609Q34986428-5E6A5F3C-813A-4A51-B8E2-621970984312Q35515150-FD577638-F9A2-4E6A-936F-F2832F94004DQ35771166-482A3010-EEC6-490F-BAC5-07F0F0E64338Q36711751-D6ECBFBB-65C1-4D19-8E8F-089E958B7ABFQ37347492-2042F9A7-7D89-4FFE-B198-2332F1E14EF7Q37506977-EAA1FDE8-C341-477D-AB04-28A010A9AAA7Q37563875-5C9CD04E-5743-431E-BDCD-0606804AED3CQ37713417-09FE2D47-5048-485C-8B7B-6BC2C4C9E457Q38101840-F1162E1B-7803-4500-BDB1-A36A03E7E4E4Q38135708-89BF2043-60E4-4BF7-B0D0-CD7F0C5CE4D7Q38168635-211A83D4-E53C-406B-A7E5-367CBBD60FB7Q38177806-4378FAF2-F3A3-4012-953C-B178C4BFB499Q38264783-55E4ECFB-9A53-4F0D-A89C-5C90F0CBCD71Q38362692-2F075ADC-E92F-431F-9F87-DAD50DEB3740Q38387844-8C18CA82-1811-4126-A99C-B1F36F143404Q38654668-2A3EFF25-B244-4EE9-83FA-A9CD8FCC5546Q38781628-7D33E9BC-6B6D-4479-B6DF-D951C1300A99Q38837940-E2D9A2D0-D202-4495-B083-2D36674FEAF5Q38984178-82D3607E-548A-4759-857D-A34CFDE3699AQ39006967-158E0025-FC7B-4C81-9745-E0AA1EF9F79EQ40227529-254492BA-3432-429F-B9B6-E360C2F2198EQ40374784-B1D4D262-BEC3-4414-8968-918DF30D4E91Q41288229-A86CF81D-4FEE-4E52-8178-76DE2D0755FAQ41334584-906BC3A7-5D3F-4172-BB1E-3DEFC2D51956Q42007027-A0F2B580-2877-4F4D-B0A1-D8EFD85299B3Q42677918-5EC75389-2216-4B40-9F72-F720E1B0D237Q42702939-CB1A85B5-CD78-4E81-A707-C7B9F02F8142Q44102830-E93E3155-1721-44A1-B792-5543229975D8Q45342738-FDAC54BD-02D9-45F4-805F-A36180C4AF89Q45985789-723C5087-E031-4104-AB90-5BBED918F8A6Q47122710-50C221FF-9C1C-4A22-B718-1373871F4121Q47821798-2CC7DC95-29D0-4509-A478-E83A9D805222
P2860
Dose escalation for prostate cancer radiotherapy: predictors of long-term biochemical tumor control and distant metastases-free survival outcomes.
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Dose escalation for prostate c ...... stases-free survival outcomes.
@ast
Dose escalation for prostate c ...... stases-free survival outcomes.
@en
type
label
Dose escalation for prostate c ...... stases-free survival outcomes.
@ast
Dose escalation for prostate c ...... stases-free survival outcomes.
@en
prefLabel
Dose escalation for prostate c ...... stases-free survival outcomes.
@ast
Dose escalation for prostate c ...... stases-free survival outcomes.
@en
P2093
P2860
P1433
P1476
Dose escalation for prostate c ...... stases-free survival outcomes.
@en
P2093
Anthony Fidaleo
Dahlia Sperling
Joanne F Chou
Laura Happersett
Marisa Kollmeier
Michael J Zelefsky
Michael Schechter
Yoshiya Yamada
P2860
P304
P356
10.1016/J.EURURO.2011.08.029
P407
P577
2011-08-22T00:00:00Z